Berkshire Grey, Inc.

2023 Q1 Form 10-Q Financial Statement

#000095017023021178 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.74M $139.6M
YoY Change -72.25% 70.82%
Cash & Equivalents $38.70M $139.6M
Short-Term Investments
Other Short-Term Assets $988.0K $5.504M
YoY Change -82.05% -11.3%
Inventory $11.48M $3.890M
Prepaid Expenses $3.421M $4.641M
Receivables $12.14M $15.25M
Other Receivables $0.00 $0.00
Total Short-Term Assets $84.54M $190.1M
YoY Change -55.53% 107.84%
LONG-TERM ASSETS
Property, Plant & Equipment $9.885M $9.411M
YoY Change 5.04% -8.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $849.0K
YoY Change -97.29% -63.93%
Total Long-Term Assets $18.42M $19.28M
YoY Change -4.45% 52.36%
TOTAL ASSETS
Total Short-Term Assets $84.54M $190.1M
Total Long-Term Assets $18.42M $19.28M
Total Assets $103.0M $209.4M
YoY Change -50.83% 101.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.614M $7.184M
YoY Change 5.99% 194.91%
Accrued Expenses $11.06M $15.13M
YoY Change -26.94% 162.71%
Deferred Revenue $27.87M $35.63M
YoY Change -21.79%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $47.60M $58.79M
YoY Change -19.03% 96.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.33M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $15.33M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.60M $58.79M
Total Long-Term Liabilities $15.33M $0.00
Total Liabilities $62.93M $82.79M
YoY Change -23.99% 42.62%
SHAREHOLDERS EQUITY
Retained Earnings -$444.4M -$328.7M
YoY Change 35.22%
Common Stock $25.00K $24.00K
YoY Change 4.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.03M $126.6M
YoY Change
Total Liabilities & Shareholders Equity $103.0M $209.4M
YoY Change -50.83% 101.09%

Cashflow Statement

Concept 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39768
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Berkshire Grey, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2994421
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001824734
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
140 South Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
CY2023Q1 dei City Area Code
CityAreaCode
833
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
848-9900
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38739000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
478219000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444367000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64322000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12135000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5006000
CY2023Q1 us-gaap Inventory Net
InventoryNet
11483000
CY2022Q4 us-gaap Inventory Net
InventoryNet
8090000
CY2023Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
9917000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
3971000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3421000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4293000
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7854000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7333000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
988000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1254000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
84537000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
94269000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9885000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10810000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7257000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7485000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1254000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1254000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23000
CY2023Q1 us-gaap Assets
Assets
102956000
CY2022Q4 us-gaap Assets
Assets
113841000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7614000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5290000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11056000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10698000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
27868000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15923000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1060000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1039000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
47598000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32950000
CY2023Q1 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
2139000
CY2022Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
1089000
CY2023Q1 bgry Warrant Liability
WarrantLiability
4875000
CY2022Q4 bgry Warrant Liability
WarrantLiability
885000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8314000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8590000
CY2023Q1 us-gaap Liabilities
Liabilities
62926000
CY2022Q4 us-gaap Liabilities
Liabilities
43514000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
25000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
484411000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-407878000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-39000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-12000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-39000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
40030000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
70327000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102956000
CY2022Q1 bgry Adjustments To Additional Paid In Capital Equity Reclassification Of Restricted Stock To Equity
AdjustmentsToAdditionalPaidInCapitalEquityReclassificationOfRestrictedStockToEquity
706000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4408000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23566000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113841000
CY2023Q1 us-gaap Revenues
Revenues
6309000
CY2022Q1 us-gaap Revenues
Revenues
5492000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
8306000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
6696000
CY2023Q1 us-gaap Gross Profit
GrossProfit
-1997000
CY2022Q1 us-gaap Gross Profit
GrossProfit
-1204000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10149000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7662000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5724000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1489000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14748000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20343000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
30621000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
29494000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32618000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30698000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
111000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000
CY2023Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-3990000
CY2022Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
7183000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36487000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23556000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-36489000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23566000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36489000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23573000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
241599990
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
241599990
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231990998
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231990998
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
70327000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
480000
CY2023Q1 bgry Adjustments To Additional Paid In Capital Equity Reclassification Of Restricted Stock To Equity
AdjustmentsToAdditionalPaidInCapitalEquityReclassificationOfRestrictedStockToEquity
279000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4152000
CY2023Q1 bgry Adjustments To Additional Paid In Capital Warrant Provision
AdjustmentsToAdditionalPaidInCapitalWarrantProvision
1281000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-36489000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
40030000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
144231000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
823000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
126595000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-36489000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23566000
CY2023Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
1085000
CY2022Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
760000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2023Q1 us-gaap Line Of Credit Assumed1
LineOfCreditAssumed1
0
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3990000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7183000
CY2022Q1 us-gaap Line Of Credit Assumed1
LineOfCreditAssumed1
884000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-33000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5482000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
-1838000
CY2023Q1 bgry Warrant Provision
WarrantProvision
1710000
CY2022Q1 bgry Warrant Provision
WarrantProvision
0
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7129000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1962000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3393000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1249000
CY2023Q1 bgry Increase Decrease In Deferred Fulfillment Costs
IncreaseDecreaseInDeferredFulfillmentCosts
5946000
CY2022Q1 bgry Increase Decrease In Deferred Fulfillment Costs
IncreaseDecreaseInDeferredFulfillmentCosts
13552000
CY2023Q1 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
521000
CY2022Q1 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
-1598000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-940000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1469000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2308000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
348000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
354000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-553000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
11945000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
16417000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-256000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-34000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25931000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32238000
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
140000
CY2022Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
46000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-140000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
480000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
822000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
480000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
822000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-46000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25583000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31508000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65576000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171951000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39993000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140443000
CY2023Q1 bgry Right Of Use Asset Non Cash And Non Financing Activities
RightOfUseAssetNonCashAndNonFinancingActivities
0
CY2022Q1 bgry Right Of Use Asset Non Cash And Non Financing Activities
RightOfUseAssetNonCashAndNonFinancingActivities
8154000
CY2023Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
CY2022Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
10287000
CY2023Q1 bgry Property Plant And Equipment Included In Accounts Payable And Accrued Expenses
PropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
20000
CY2022Q1 bgry Property Plant And Equipment Included In Accounts Payable And Accrued Expenses
PropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
147000
CY2023Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
30047000
CY2022Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
129172000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38739000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139581000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1254000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
862000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39993000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140443000
CY2023Q1 dei Entity Number Of Employees
EntityNumberOfEmployees
280
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444400000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38700000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates and judgments include, but are not limited to, revenue recognition (including performance obligations, provisions for contract losses, variable consideration, impact of the FedEx warrant, and other obligations such as product returns), realizability of deferred fulfillment costs, inventory, warranty cost, accounting for stock-based compensation (including performance-based assessments), and accounting for income taxes and related valuation allowances. Actual results may differ from estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Provision For Loss On Contracts
ProvisionForLossOnContracts
600000
CY2022Q4 us-gaap Provision For Loss On Contracts
ProvisionForLossOnContracts
2700000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially expose the Company to concentrations of credit risk consist of accounts receivable and cash and cash equivalents.</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of the Company’s products are concentrated among specific customers. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023, and December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customers accounted for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Company’s accounts receivable balance, respectively. For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company generated </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of revenues from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> respective customers. For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company generated approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of revenues from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> respective customers. The Company believes that credit risks associated with these contracts are not significant due to the customers’ financial strength.</span></p><p style="text-indent:4.44%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company places cash and cash equivalents with high-quality financial institutions. The Company is exposed to credit risk in the event of default by these institutions to the extent the amount recorded on the condensed consolidated balance sheets exceeds federally insured limits.</span></p>
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2023Q1 bgry Compulsory Conversion Price
CompulsoryConversionPrice
1.40
CY2023Q1 bgry Initial Conversion Price Of Common Stock
InitialConversionPriceOfCommonStock
1.40
CY2023Q1 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.2000
CY2023Q1 us-gaap Debt Instrument Interest Rate Increase Decrease
DebtInstrumentInterestRateIncreaseDecrease
0.2500
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11500000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8100000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17438000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17549000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7553000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6739000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9885000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10810000
CY2023Q1 us-gaap Depreciation
Depreciation
1100000
CY2022Q1 us-gaap Depreciation
Depreciation
800000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1697000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5146000
CY2023Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
663000
CY2022Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
192000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2673000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
813000
CY2023Q1 bgry Accrued Materials Current
AccruedMaterialsCurrent
3743000
CY2022Q4 bgry Accrued Materials Current
AccruedMaterialsCurrent
2950000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1600000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
777000
CY2023Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
680000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
820000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11056000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10698000
CY2023Q1 us-gaap Compensated Absences Liability
CompensatedAbsencesLiability
1200000
CY2022Q4 us-gaap Compensated Absences Liability
CompensatedAbsencesLiability
4000000.0
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
820000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
452000
CY2023Q1 us-gaap Standard Product Warranty Accrual Preexisting Increase Decrease
StandardProductWarrantyAccrualPreexistingIncreaseDecrease
-216000
CY2022 us-gaap Standard Product Warranty Accrual Preexisting Increase Decrease
StandardProductWarrantyAccrualPreexistingIncreaseDecrease
-427000
CY2023Q1 bgry Warranty Costs Incurred During Period
WarrantyCostsIncurredDuringPeriod
76000
CY2022 bgry Warranty Costs Incurred During Period
WarrantyCostsIncurredDuringPeriod
795000
CY2023Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
680000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
820000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6309000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5492000
CY2023Q1 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
9900000
CY2022Q4 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
4000000.0
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15923000
CY2023Q1 bgry Contract Liabilities Incurred During The Period
ContractLiabilitiesIncurredDuringThePeriod
20380000
CY2023Q1 us-gaap Contract With Customer Asset Allowance For Credit Loss Period Increase Decrease
ContractWithCustomerAssetAllowanceForCreditLossPeriodIncreaseDecrease
-2126000
CY2023Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-3809000
CY2023Q1 bgry Contract With Customer Liabilities Incurred During The Period Revenue Recognized
ContractWithCustomerLiabilitiesIncurredDuringThePeriodRevenueRecognized
-2500000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
27868000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7333000
CY2023Q1 bgry Contract Assets Incurred During The Period
ContractAssetsIncurredDuringThePeriod
521000
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7854000
CY2019Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
9900000
CY2019Q4 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.0186
CY2019Q4 bgry Relatedpartytransactionliablepercentage
Relatedpartytransactionliablepercentage
0.51
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5482000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-1838000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2938257
CY2021Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1023825
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q1 bgry Public And Private Warrant Value Trading Price
PublicAndPrivateWarrantValueTradingPrice
330
CY2023Q1 bgry Fairvalueequitylevel1 Tolevel2 Tolevel3 Transfersamount
Fairvalueequitylevel1Tolevel2Tolevel3Transfersamount
0
CY2023Q1 bgry Income Tax Expense Benefit To Future Taxable Income
IncomeTaxExpenseBenefitToFutureTaxableIncome
0
CY2022Q1 bgry Income Tax Expense Benefit To Future Taxable Income
IncomeTaxExpenseBenefitToFutureTaxableIncome
0
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.00004
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0005
CY2023Q1 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
one-for-one
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Revenues
Revenues
6309000
CY2022Q1 us-gaap Revenues
Revenues
5492000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1100000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8300000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1101000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1504000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1473000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1287000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1326000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4466000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11157000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1771000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
9386000
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14750000
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10.00
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0520
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0027
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y

Files In Submission

Name View Source Status
0000950170-23-021178-index-headers.html Edgar Link pending
0000950170-23-021178-index.html Edgar Link pending
0000950170-23-021178.txt Edgar Link pending
0000950170-23-021178-xbrl.zip Edgar Link pending
bgry-20230331.htm Edgar Link pending
bgry-20230331.xsd Edgar Link pending
bgry-ex31_1.htm Edgar Link pending
bgry-ex31_2.htm Edgar Link pending
bgry-ex32_1.htm Edgar Link pending
bgry-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
bgry-20230331_lab.xml Edgar Link unprocessable
bgry-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bgry-20230331_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bgry-20230331_cal.xml Edgar Link unprocessable
bgry-20230331_def.xml Edgar Link unprocessable